tirzepatide and hyperthyroidism Raises Thyroid Risk in Certain At-Risk Patients Can You Take GLP-1 With

(2024) examined 9,465 patients with type 2 diabetes undergoing THA, comparing 1,653 semaglutide users to a matched control group of 7,812 non-users

That vagueness is worth flagging

This is especially important considering the increasing use of these medications. The authors write that, to their knowledge, this is the first case detailing a patient developing this serious condition after starting tirzepatide for diabetes (in contrast to those treated with tirzepatide for weight loss)

Lancet 1 , 10751078 (1981)

GLP-1 receptor agonists provide targeted control for type 2 diabetes and obesity in children by delaying gastric emptying, slowing glucose absorption